FDA has introduced a new program for medical devices and for device led combination products. Under this program are...
Results for "diagnostic technologies"
EMMA International’s Commitment to Supporting Early Detection Initiatives
Prostate cancer has emerged as the most commonly diagnosed cancer among men in the UK, with about 1 in 8 men affected during their lifetime. Early detection is vital as it significantly boosts survival rates and enhances treatment outcomes. Cutting-edge diagnostics, such as Oxford BioDynamics’ EpiSwitch PSE blood test—which boasts a remarkable 94% accuracy rate—are setting new standards in early prostate cancer diagnosis, outperforming traditional tests like the PSA.
Digital Traceability Is Becoming a Regulatory Expectation — Not a Competitive Advantage
Across regulated industries, digital traceability is no longer viewed as a strategic enhancement. It is quickly becoming a regulatory expectation. From pharmaceuticals and medical devices to aerospace, defense, and advanced manufacturing, oversight bodies are placing greater emphasis on transparency, data integrity, and real-time visibility into operations.
Software Engineer
Full Stack EngineerAre you passionate about AI and excited to build a platform from the ground up? EMMA International...
Healthcare’s Digital Transformation: Telemedicine, Data Protection, and Cybersecurity
Telemedicine has evolved from a supplemental offering into a foundational component of modern healthcare delivery. Virtual consultations, remote diagnostics, and digital patient engagement have improved access to care, reduced logistical barriers, and supported continuity across care settings. These technologies have become especially valuable in addressing workforce shortages and extending care to underserved populations.
MDCG Issues New Guidance on Breakthrough Medical Devices Under EU MDR and IVDR
The European Commission’s Medical Device Coordination Group (MDCG) has issued new guidance clarifying how medical devices and in vitro diagnostics can qualify as breakthrough devices under the EU Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR). The guidance establishes a formal EU-level framework intended to support innovative technologies while maintaining robust clinical and performance evidence requirements.
Stakeholders Urge Withdrawal of Several Draft Guidances on 510(k) Submissions and Thermal Effects
Industry groups are calling for the withdrawal of multiple draft guidances related to 510(k) submissions and the evaluation of medical devices that generate tissue heating or cooling. Commenters argue that the documents are overly broad, inconsistent with longstanding regulatory practices, and risk imposing burdens that could slow medtech innovation.
FDA Seeks Public Input on Evaluating AI-Enabled Medical Devices
Artificial intelligence (AI) continues to revolutionize healthcare, transforming how data is interpreted, diagnoses are made, and patient care is delivered. However, with these advancements come new regulatory challenges—particularly around ensuring safety, performance, and reliability over time. To address these issues, the U.S. Food and Drug Administration (FDA) has released a discussion paper through its Center for Devices and Radiological Health (CDRH), seeking public feedback on how to assess AI-enabled medical devices across their entire product lifecycle.
Euro Roundup: AI Consultation, Clinical Trial Guidelines, and Regulatory Shifts Across Europe
The European regulatory landscape continues to evolve rapidly, with new initiatives aimed at balancing innovation, safety, and patient access. This week’s developments span artificial intelligence in medicine, updated clinical trial guidance, new requirements for diagnostics, and broader efforts to simplify Europe’s complex regulatory framework.
FDA Lists Its Upcoming Research Priorities for Generic Drugs
Generic drugs remain essential for healthcare systems worldwide, but evolving formulations, delivery systems, and safety concerns require increasingly sophisticated approaches to regulation. FDA’s updated priorities aim to strengthen scientific understanding, modernize review processes, and make the development of generics more efficient.